Melanoma

Melanoma Treatment Trials

Protocol
Number

Title

ID

Biovex
Extension
005/05
SLHN
2010 -76

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence

Learn more.

NCT01667419 
Novartis
MEK
162A2301
SLHN
2013-54

Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive melanoma.

Learn more.

NCT01763164
Genentech
Roche
GO27826

This multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patients will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo.

Learn more.

NCT 01667419
BMS
CA184143

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting.

Learn more.

NCT01511913
ZIOPHARM
AT 1001 101
SLHN
2012- 86

A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma

Learn more.

NCT01397708
Prometheus
12PLK01

A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma

Learn more.

NCT01683188
ECOG
2607

A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral, and Solar Melanomas

Learn more.

NCT00700882
ECOG
1609

A Phase III Randomized Study of Adjuvant Ipilimimab Anti-CTLA4 Therapy vs. High-Dose Interferon Alpha-2b for Resected High Risk Melanoma

Learn more.

NCT01274338

SLHN
2009-84
Provectus
PV10-
EA02

Open Label Expanded Access for Investigational Use of PV-10 in Patients who are not Eligible for an Existing PV-10 Clinical Trial for whom there is no Comparable or Satisfactory Approved Alternative Therapy & Whom in the Opinion of the Investigator may Benefit from PV-10 Administration NCT 0120779
SLHN
2005-22
MSLT-II

A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy alone in Cutaneous Melanoma Patients with Molecular or Histopatholgical Evidence of Metastases in the Sentinel Node

Learn more.

NCT00297895